Purpose: To present intermediate-term oncologic efficacy of cryoablation (CA) for the treatment of patients with small renal masses in a multi-institution multisurgeon cohort.
Patients And Methods: We retrospectively reviewed billing records and tumor registries, identifying 116 renal tumors in 116 patients treated with CA by six surgeons at four institutions. Patient age, sex, tumor size, RENAL nephrometry score, complications, and recurrences were recorded.
Results: One hundred-sixteen patients (66.4% male, 33.6% female) with 116 tumors underwent renal mass CA with a mean follow-up of 27.4 months (range 1-112 mos). Mean tumor size was 2.76 ± 0.97 cm (range 1.1-5.5 cm). Twenty-seven complications occurred in 23 patients for an overall complication rate of 19.8%. Low-grade complications (Clavien I and II) accounted for 92.6% (n=25) of overall complications. Seven (6%) patients had enhancement on initial imaging and were considered incomplete ablations. Local recurrence and metastatic disease developed in four and one patients, respectively. In patients with biopsy-proven renal-cell carcinoma (RCC), the 2- and 5-year recurrence-free survival (RFS) probability was 0.83 (95% confidence interval [CI]: 0.74, 0.95) and 0.77 (95% CI: 0.60, 0.94), respectively. After excluding biopsy proven RCC patients with incomplete ablations, the 2- and 5-year RFS increased to 0.91 (95% CI: 0.82, 1.00) and 0.85 (95% CI: 0.71, 1.00) respectively.
Conclusion: CA of renal masses results in acceptable oncologic efficacy accompanied by a tolerable complication profile in a cohort with a mean follow-up of 27.4 months. CA remains a viable treatment option for small renal masses in selected patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/end.2011.0179 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concordance of surgical treatment selection with the AUA guidelines for localized renal masses.
Urol Oncol
January 2025
College of Human Medicine, Michigan State University, Grand Rapids, MI; Division of Urology, Corewell Health West, Grand Rapids, MI. Electronic address:
Objective: To examine and evaluate guideline concordance of surgical treatment selection at a community-based health system. The AUA guidelines provide specific guidance regarding appropriate utilization of radical nephrectomy (RN) and partial nephrectomy (PN). However, nearly 40% of patients did not fit a guideline-specified scenario in a prior report.
View Article and Find Full Text PDFCECT-Based Radiomic Nomogram of Different Machine Learning Models for Differentiating Malignant and Benign Solid-Containing Renal Masses.
J Multidiscip Healthc
January 2025
Department of Nuclear Medicine, The First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650032, People's Republic of China.
Objective: This study aimed to explore the value of a radiomic nomogram based on contrast-enhanced computed tomography (CECT) for differentiating benign and malignant solid-containing renal masses.
Materials And Methods: A total of 122 patients with pathologically confirmed benign (n=47) or malignant (n=75) solid-containing renal masses were enrolled in this study. Radiomic features were extracted from the arterial, venous and delayed phases and further analysed by dimensionality reduction and selection.
Lack of effect of renal function on uptake of 99mTc-sestamibi in renal masses.
Nucl Med Commun
January 2025
Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, North Carolina.
Objective: The appropriate clinical management of indeterminate small renal masses can be improved based on accurate risk stratification. This study aimed to investigate the impact of renal function on the uptake of technetium-99m (99mTc)-sestamibi, a widely available imaging agent that can be utilized to identify oncocytomas and other benign/indolent renal masses.
Methods: A retrospective cohort study was conducted, involving 100 consecutive patients who underwent 99mTc-sestamibi single-photon emission computed tomography/computed tomography.
Tumour size is associated with growth rates of >0.5 cm/year and delayed intervention in small renal masses in patients on active surveillance.
BJU Int
January 2025
Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Objective: To evaluate the association between tumour size and the growth rate (GR) of small renal masses (SRMs) in patients managed by active surveillance (AS).
Materials And Methods: We queried the prospective, multi-institutional Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) registry for patients on AS with an imaging interval of ≥6 months, identifying 456 patients. We tracked tumour size over time; a GR >0.
Ethical dilemmas surrounding patients´ "unwise" treatment preferences and suboptimal decision quality: case series of three renal cell carcinoma patients who developed local recurrences after non-guideline-concordant care choices.
Pan Afr Med J
January 2025
College of Medicine, Qatar University, Doha, Qatar.
Patient engagement and shared decision-making (SDM) between patients and clinicians is the foundation of patient-centered care. It aims to reach a treatment option that fits the patient's preference and is guideline-concordant. We sought to evaluate the possible causes and outcomes of patient's non-guideline-concordant care choices.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!